By Josh Beckerman
Pulse Biosciences shares rose 16% after the bioelectric medicine company issued product updates and said controlling stockholder and Chairman Robert W. Duggan is evaluating potential purchases of company stock.
The stock was recently at $8.47 and has more than quadrupled over the last 52 weeks.
Pulse has received all regulatory approvals for a planned catheter ablation feasibility study for its CellFX nsPFA Cardiac Catheter and said the first study procedures are scheduled for mid-December.
Additionally, Pulse said it anticipates filing a 510(k) submission with the Food and Drug Administration for its CellFX nsPFA Cardiac Clamp by the end of the January, and said a December filing is possible.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
11-27-23 1536ET